Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.55 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.44 |
| ▸ | FEN1 | P39748 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13690495 | 1.00 | GPR119 (0.55) | GPR119ALOX5APFEN1HDAC1CHEK2 | |
| SCHEMBL4049899 | 0.88 | SPHK2 (0.44) | GPR119ROCK2SPHK2SPHK1 | |
| SCHEMBL4048867 | 0.88 | SPHK2 (0.44) | GPR119ROCK2SPHK2SPHK1 | |
| SCHEMBL14191531 | 0.86 | GPR119 (0.51) | GPR119HDAC1CHEK2ROCK2 | |
| SCHEMBL13690526 | 0.85 | GPR119 (0.48) | GPR119HDAC1ROCK2 | |
| SCHEMBL13690346 | 0.85 | GPR119 (0.48) | GPR119HDAC1ROCK2 | |
| SCHEMBL13690475 | 0.84 | GPR119 (0.59) | GPR119ALOX5APFEN1HDAC1CHEK2 | |
| SCHEMBL13690462 | 0.84 | GPR119 (0.57) | GPR119ALOX5APFEN1HDAC1CHEK2 | |
| SCHEMBL13690558 | 0.83 | GPR119 (0.58) | GPR119ALOX5APFEN1HDAC1CHEK2 | |
| SCHEMBL13690457 | 0.83 | GPR119 (0.56) | GPR119ALOX5APFEN1HDAC1CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009106561-A1 | PYRAZINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2009-09-03 | — | — | WO | disclosed |